Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
about
Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancyIbrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.Chronic lymphocytic leukemia (CLL)-Then and now.The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.Current Treatment of Chronic Lymphocytic Leukemia.Advances in the treatment of relapsed/refractory chronic lymphocytic leukemiaCurrent Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.Ibrutinib may impair serological responses to influenza vaccination.The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activationIncidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.Severe hepatitis B virus reactivation related to ibrutinib monotherapy.Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib.The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study.Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.Is HBV prophylaxis required during CLL treatment with ibrutinib?Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark.Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosisInvasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target DrugsMemory B cells are reactivated in subcapsular proliferative foci of lymph nodesImmunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia
P2860
Q28080304-AB556AE2-8A56-46A2-88A4-7B2C76DD1129Q30252869-517E152B-8081-4C20-B156-60819D00559BQ37708827-3035415A-40FB-43C6-923A-FD1CA05A0922Q37709461-AFDF18B7-E972-41F5-8425-2AE3E0F84E6BQ38675358-BF1032DA-5193-4A42-99D8-DFBB9669176DQ38719429-4F21A057-26C0-4FB8-96FE-294C97CFF8D2Q38728631-6C8B91DF-BFD3-424E-807F-5566F1EB3671Q38818283-A4717E2D-B438-4583-AEA6-2653294E40CBQ39026190-2DEE7247-BF12-4498-916C-24763B243DC9Q39129372-452102FE-3D08-4B53-945C-426AB6F0037AQ39227773-02A31862-5129-4BA5-8B8F-EDD94D215AF5Q39325783-A0EDB728-3521-4C03-8118-A24A40D86625Q40126133-5D3FFFCC-0431-4D95-9528-02A8A6F8ACA9Q40139755-1A3A9C55-7E06-412F-82D7-3956172B7C35Q40154480-DDE9C1A9-36CC-474E-B4E7-DBB0946BFCA8Q42336336-9BF703F6-6662-44D5-BC48-CDF21BAA2DC8Q42368314-ABF5423B-CA3E-4624-85C7-5A1A96EFF304Q42383009-0319AF46-B3E9-4B47-9E4A-51E396E87EBDQ45331146-BE385CD3-C86B-4D19-AACA-536A007BB476Q46418074-58BC4560-A538-49D8-973A-70D9F3EB62E1Q46566477-271D313A-F6EB-4F0E-9182-1429233383B5Q47102996-84787000-3A30-4748-A3D8-E9932491F3DEQ47424531-F030388D-A2A2-418C-A224-8290671728CBQ47820958-FC4655E5-A9E0-434F-B3F4-218A7FA9AA1AQ47875518-4713B47E-D209-4810-8E12-7B602ED658C7Q48060895-A9349F78-3718-4F46-9637-07A8D7FE7A29Q48125213-519430E9-3CED-4702-93EF-589A43EFB330Q48273854-5C30580E-605B-4F01-B2F8-363E71BD64F2Q50578195-CE767373-FC10-4193-B5F2-EC282ECDFC53Q52684522-4802EC34-CAD3-4679-B75C-7AA2144D7EAFQ53963822-126B5832-82EE-4DC2-A3B6-755DC884DBC8Q54116803-3CD39AAB-5F2B-493D-A0F9-382DA7DB05E0Q54653633-099DBA7F-6EAB-4024-906A-B2C2F5ACAC63Q55648068-D9026053-4161-4D03-BF12-91915423A5B3Q58609454-5485D330-5D1A-4E90-AA59-A4E26A62C052Q58701117-CE4EA01A-2EB7-45D4-B032-6C550F617F61Q58722256-207520F6-1930-40B0-9568-7294F043C4A4Q58744741-6439FE73-B516-4C03-B51F-09D90506039A
P2860
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Partial reconstitution of humo ...... ukemia treated with ibrutinib.
@ast
Partial reconstitution of humo ...... ukemia treated with ibrutinib.
@en
type
label
Partial reconstitution of humo ...... ukemia treated with ibrutinib.
@ast
Partial reconstitution of humo ...... ukemia treated with ibrutinib.
@en
prefLabel
Partial reconstitution of humo ...... ukemia treated with ibrutinib.
@ast
Partial reconstitution of humo ...... ukemia treated with ibrutinib.
@en
P2093
P2860
P50
P1433
P1476
Partial reconstitution of humo ...... ukemia treated with ibrutinib.
@en
P2093
Abner L Notkins
Adrian Wiestner
Andrew Lipsky
Constance Yuan
Gerald E Marti
Irina Maric
Janet Valdez
Lela Kardava
Maryalice Stetler-Stevenson
P2860
P304
P356
10.1182/BLOOD-2015-04-639203
P407
P577
2015-09-03T00:00:00Z